Literature DB >> 3493072

A 6-thioguanine-resistant variant of the rat mammary adenocarcinoma 13762 that is more immunogenic.

D S Hoon, I A Ramshaw.   

Abstract

A 6-thioguanine-resistant (TgR) variant of the metastatic mammary tumor 13762 was found to be very immunogenic. This TgR variant was nontumorigenic and nonmetastatic, whereas the parent 13762 cell line is very tumorigenic and metastatic in normal syngeneic animals. The TgR variant was tumorigenic in irradiated animals. The mechanism of the hosts' immune rejection of this TgR variant was investigated. A 51Cr-release cytotoxic cell assay was used to assess lymphocyte cell-mediated cytotoxicity (CMC) of tumor-draining lymph nodes and spleens from animals injected with tumor cells. In a secondary CMC response of splenic T cells from animals injected with TgR cells, there was a much stronger response as compared to animals injected with 13762 cells. This strong cytotoxic T cell response was short-term and correlated to the host rejection of TgR cells. Previously, we selected revertant cell lines (TgRrev, TgRrevM) from the TgR variant line that were more metastatic and tumorigenic. The revertant cell lines induced a lower CMC response than the TgR line, but a higher response compared to the parent 13762 line. The poor CMC response from 13762 tumor-bearing animals was investigated and appeared to be due to a suppressor T cell response.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3493072     DOI: 10.1007/BF00199831

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Mechanism of cell-mediated cytotoxicity at the single cell level. I. Estimation of cytotoxic T lymphocyte frequency and relative lytic efficiency.

Authors:  E Grimm; B Bonavida
Journal:  J Immunol       Date:  1979-12       Impact factor: 5.422

Review 2.  Suppressor cells: permitters and promoters of malignancy?

Authors:  D Naor
Journal:  Adv Cancer Res       Date:  1979       Impact factor: 6.242

3.  Regulation of the immune response. II. Repressor T cells in cyclophosphamide-induced tolerant mice.

Authors:  I A Ramshaw; P A Bretscher; C R Parish
Journal:  Eur J Immunol       Date:  1977-03       Impact factor: 5.532

4.  The lymphocyte surface. II. Separation of Fc receptor, C'3 receptor and surface immunoglobulin-bearing lymphocytes.

Authors:  C R Parish; J A Hayward
Journal:  Proc R Soc Lond B Biol Sci       Date:  1974-08-27

5.  Natural cytotoxicity of mouse, rat, and human lymphocytes against heterologous target cells.

Authors:  M E Nunn; R B Herberman
Journal:  J Natl Cancer Inst       Date:  1979-04       Impact factor: 13.506

6.  Circulating immune complexes in rats bearing 6-thioguanine-resistant variants of the 13762 mammary adenocarcinoma.

Authors:  D B Hoon; B Ziola; I Ramshaw
Journal:  Cancer Res       Date:  1984-06       Impact factor: 12.701

7.  Macrophages suppress CTL generation in rat mixed leukocyte cultures.

Authors:  A Weiss; F W Fitch
Journal:  J Immunol       Date:  1977-08       Impact factor: 5.422

8.  Membrane-associated alterations detected in poorly tumorigenic lectin-resistant variant sublines of a highly malignant and metastatic murine tumor.

Authors:  J W Dennis; T P Donaghue; R S Kerbel
Journal:  J Natl Cancer Inst       Date:  1981-01       Impact factor: 13.506

9.  Abrogation of the in vitro generation of the cytotoxic T-cell response to a murine tumor: the role of suppressor cells.

Authors:  P Frost; P Prete; R Kerbel
Journal:  Int J Cancer       Date:  1982-08-15       Impact factor: 7.396

10.  Immunogenic variants obtained by mutagenesis of mouse mastocytoma P815. II. T lymphocyte-mediated cytolysis.

Authors:  T Boon; J Van Snick; A Van Pel; C Uyttenhove; M Marchand
Journal:  J Exp Med       Date:  1980-11-01       Impact factor: 14.307

View more
  1 in total

1.  Augmented induction of antitumor cells in vivo by cyclophosphamide fails to benefit antitumor resistance of the host.

Authors:  K Ryoyama; C Ryoyama
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.